Polyethylene Glycol 3350 With Electrolytes Versus Polyethylene Glycol 4000 for Constipation: A Randomized, Controlled Trial

Noor L H Bekkali, Daniël R Hoekman, Olivia Liem, Marloes E J Bongers, Michiel P van Wijk, Bas Zegers, Rolf A Pelleboer, Wim Verwijs, Bart G P Koot, Maksym Voropaiev, Marc A Benninga, Noor L H Bekkali, Daniël R Hoekman, Olivia Liem, Marloes E J Bongers, Michiel P van Wijk, Bas Zegers, Rolf A Pelleboer, Wim Verwijs, Bart G P Koot, Maksym Voropaiev, Marc A Benninga

Abstract

Objective: The long-term efficacy and safety of polyethylene glycol (PEG) in constipated children are unknown, and a head-to-head comparison of the different PEG formulations is lacking. We aimed to investigate noninferiority of PEG3350 with electrolytes (PEG3350 + E) compared to PEG4000 without electrolytes (PEG4000).

Methods: In this double-blind trial, children aged 0.5 to 16 years with constipation, defined as a defecation frequency of <3 times per week, were randomized to receive either PEG3350 + E or PEG4000. Primary outcomes were change in total sum score (TSS) at week 52 compared to baseline, and dose range determination. TSS was the sum of the severity of 5 constipation symptoms rated on a 4-point scale (0-3). Noninferiority margin was a difference in TSS of ≤1.5 based on a 95%-confidence interval [CI]. Treatment success was defined as a defecation frequency of ≥3 per week with <1 episode of fecal incontinence.

Results: Ninety-seven subjects were included, of whom 82 completed the study. Mean reduction in TSS was -3.81 (95% CI: -4.96 to -2.65) and -3.74 (95%CI: -5.08 to -2.40), for PEG3350 + E and PEG4000, respectively. Noninferiority criteria were not met (maximum difference between groups: -1.81 to 1.68). Daily sachet use was: 0 to 2 years: 0.4 to 2.3 and 0.9 to 2.1; 2 to 4 years: 0.1 to 3.5 and 1.2 to 3.2; 4 to 8 years: 1.1 to 2.8 and 0.7 to 3.8; 8 to 16 years 0.6 to 3.7 and 1.0 to 3.7, in PEG3350 + E and PEG4000, respectively. Treatment success after 52 weeks was achieved in 50% and 45% of children, respectively (P = 0.69). Rates of adverse events were similar between groups, and no drug-related serious adverse events occurred.

Conclusions: Noninferiority regarding long-term constipation-related symptoms of PEG3350 + E compared to PEG4000 was not demonstrated. However, analysis of secondary outcomes suggests similar efficacy and safety of these agents.

Trial registration: ClinicalTrials.gov NCT01810653.

Conflict of interest statement

M.V. is employed by Bayer. The other authors report no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Flow diagram of the progress through trial phases.
FIGURE 2
FIGURE 2
Average total sum score by week and treatment group. Whiskers indicate 95% confidence intervals (per-protocol population). PEG = polyethylene glycol.
FIGURE 3
FIGURE 3
Success rates of PEG3350 + E vs PEG4000 at all visits after start of treatment (intention-to-treat population). No difference was found between treatment arms. PEG = polyethylene glycol.

References

    1. Mugie SM, Benninga MA, Di Lorenzo C. Epidemiology of constipation in children and adults: a systematic review. Best Pract Res Clin Gastroenterol 2011; 25:3–18.
    1. Rasquin A, Di Lorenzo C, Forbes D, et al. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology 2006; 130:1527–1537.
    1. Tabbers MM, DiLorenzo C, Berger MY, et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr 2014; 58:258–274.
    1. Lee-Robichaud H, Thomas K, Morgan J, et al. Lactulose versus polyethylene glycol for chronic constipation. Cochrane Database Syst Rev 2010; CD007570.
    1. Brady CE, DiPalma JA, Morawski SG, et al. Urinary excretion of polyethylene glycol 3350 and sulfate after gut lavage with a polyethylene glycol electrolyte lavage solution. Gastroenterology 1986; 90:1914–1918.
    1. Hoekman DR, Benninga MA. Functional constipation in childhood: current pharmacotherapy and future perspectives. Expert Opin Pharmacother 2013; 14:41–51.
    1. Dziechciarz P, Horvath A, Szajewska H. Polyethylene glycol 4000 for treatment of functional constipation in children. J Pediatr Gastroenterol Nutr 2015; 60:65–68.
    1. Dipalma JA, Cleveland MV, McGowan J, et al. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol 2007; 102:1436–1441.
    1. Loening-Baucke V, Pashankar DS. A randomized, prospective, comparison study of polyethylene glycol 3350 without electrolytes and milk of magnesia for children with constipation and fecal incontinence. Pediatrics 2006; 118:528–535.
    1. Gordon M, Naidoo K, Akobeng A, et al. Osmotic and stimulant laxatives for the management of childhood constipation. Cochrane Database Syst Rev 2012; CD009118.
    1. NASPGHAN Neurogastroenterology and Motility Committee. Polyethylene Glycol 3350 (PEG 3350) Frequently Asked Questions [Internet]. 2015 [cited 2016 Apr 4]. Available at: .
    1. Heuckeroth R, Piccoli D. Polyethylene glycol safety in children [Internet]. [cited 2016 Apr 4]; Available at: .
    1. Seinelä L, Sairanen U, Laine T, et al. Comparison of polyethylene glycol with and without electrolytes in the treatment of constipation in elderly institutionalized patients: a randomized, double-blind, parallel-group study. Drugs Aging 2009; 26:703–713.
    1. Chaussade S, Minić M, Minic M. Comparison of efficacy and safety of two doses of two different polyethylene glycol-based laxatives in the treatment of constipation. Aliment Pharmacol Ther 2003; 17:165–172.
    1. Szojda MM, Mulder CJJ, Felt-Bersma RJF. Differences in taste between two polyethylene glycol preparations. J Gastrointestin Liver Dis 2007; 16:379–381.
    1. Couturier D. [Comparative study of Forlax and Transipeg in the treatment of functional constipation in the adult]. Ann Gastroenterol Hepatol (Paris) 1996; 32:135–140.
    1. Katelaris P, Naganathan V, Liu K, et al. Comparison of the effectiveness of polyethylene glycol with and without electrolytes in constipation: a systematic review and network meta-analysis. BMC Gastroenterol 2016; 16:42.
    1. Voskuijl W, de Lorijn F, Verwijs W, et al. PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial. Gut 2004; 53:1590–1594.
    1. Nurko S, Youssef NNN, Sabri M, et al. PEG3350 in the treatment of childhood constipation: a multicenter, double-blinded, placebo-controlled trial. J Pediatr 2008; 153:254–261.
    1. Thomson MA, Jenkins HR, Bisset WM, et al. Polyethylene glycol 3350 plus electrolytes for chronic constipation in children: a double blind, placebo controlled, crossover study. Arch Dis Child 2007; 92:996–1000.
    1. Gremse DA, Hixon J, Crutchfield A. Comparison of polyethylene glycol 3350 and lactulose for treatment of chronic constipation in children. Clin Pediatr (Phila) 2002; 41:225–229.
    1. Rafati M, Karami H, Salehifar E, et al. Clinical efficacy and safety of polyethylene glycol 3350 versus liquid paraffin in the treatment of pediatric functional constipation. Daru 2011; 19:154–158.
    1. Candy DCA, Edwards D, Geraint M. Treatment of faecal impaction with polyethelene glycol plus electrolytes (PGE + E) followed by a double-blind comparison of PEG + E versus lactulose as maintenance therapy. J Pediatr Gastroenterol Nutr 2006; 43:65–70.
    1. van Ginkel R, Reitsma JB, Büller HA, et al. Childhood constipation: longitudinal follow-up beyond puberty. Gastroenterology 2003; 125:357–363.
    1. Kuizinga-Wessel S, Heckert SL, Tros W, et al. Reporting on outcome measures of functional constipation in children—a systematic review Authors. J Pediatr Gastroenterol Nutr 2016; 62:840–846.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren